Loading
A phase 1/2 trial of Nelitolimod run by TriSalus Life Sciences, Inc., terminated.
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors is a phase 1/2 interventional study registered as NCT05220722 by TriSalus Life Sciences, Inc., with 23 participants enrolled, started 2022-03-02, primary completion reached 2024-07-31. Conditions recorded: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma. Interventions recorded: SD-101, Pembrolizumab, Nivolumab, Ipilimumab. Reason given for stopping: The decision was made to terminate the study after the completion of Phase 1b enrollment and not proceed with Phase 2. Trial termination was not due to patient safety or data concerns.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Nelitolimod, TriSalus Life Sciences and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/